We serve Chemical Name:3-[4-[(2-chloro-6-fluorophenyl)methyl]piperazin-1-yl]propan-1-amine CAS:306934-74-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![3-[4-[(2-chloro-6-fluorophenyl)methyl]piperazin-1-yl]propan-1-amine](https://a.dearchem.com/CAS2/306934-74-7.png)
Chemical Name:3-[4-[(2-chloro-6-fluorophenyl)methyl]piperazin-1-yl]propan-1-amine
CAS.NO:306934-74-7
Synonyms:3-[4-[(2-chloro-6-fluorophenyl)methyl]piperazin-1-yl]propan-1-amine
Molecular Formula:C14H21ClFN3
Molecular Weight:285.78800
HS Code:2933599090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:378.9ºC at 760 mmHg
Density:1.186g/cm3
Index of Refraction:1.553
PSA:32.50000
Exact Mass:285.14100
LogP:2.52160
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 2735
Packing Group:
Contact us for information like 3-[4-[(2-chloro-6-fluorophenyl)methyl]piperazin-1-yl]propan-1-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-[4-[(2-chloro-6-fluorophenyl)methyl]piperazin-1-yl]propan-1-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-[4-[(2-chloro-6-fluorophenyl)methyl]piperazin-1-yl]propan-1-amine Use and application,3-[4-[(2-chloro-6-fluorophenyl)methyl]piperazin-1-yl]propan-1-amine technical grade,usp/ep/jp grade.
Related News: The suit says that while BRAF kinase inhibitors existed prior to Plexxikon’s discoveries, they were not selective, and Plexxikon’s have a core molecular structure that allows them to bind selectively to kinase created by the BRAF mutation. That allows for higher doses to be administered. bilirubin manufacturers François-Henri Boissel, CEO of NOVA, commented: “Grégoire is an industry trail blazer with over two decades of experience in innovation, product strategy and digital entrepreneurship. (4-Butylmercapto-3-methyl-benzyl)-propyl-sulfid suppliers A new post-hoc analysis of pooled data from the TULIP phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR 2021) showed anifrolumab was consistently associated with improvements in both skin rash and arthritis across three different disease measures each, compared to placebo, in patients with moderate to severe systemic lupus erythematosus (SLE). 1-nitro-1-((p-nitrophenyl)thio)-2,2-diphenylethylene vendor & factory.
